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Introduction
Subependymoma is a rare, benign, slow-growing neo-
plasm that was first described by Scheinker [1] in 1945 as
a tumor arising from the subependymal cell plate.
Subependymomas are most commonly located in the
fourth and lateral ventricles, but have also been reported
arising in the third ventricle, septum pellucidum, and the
spinal canal [2–9]. Since its original description, more
than 100 case reports of intracranial subependymomas
have been described. Due to its rarity and variable
imaging characteristics, reliable pre-operative diagnosis
remains challenging [10].
The indolent growth of subependymomas is reflected
by the fact that most subependymomas are asymptom-
atic, often incidentally discovered at autopsy [2]. It has
been reported that there is a 0.7% incidence of sube-
pendymoma among 1,000 patients with pathologically
proven intracranial neoplasms versus an incidence of
only 0.4% among 1,000 asymptomatic patients at au-
topsy [11]. Subependymomas are more common in
males. Patients with symptomatic subependymomas
usually present between the fourth and sixth decades of
life with symptoms related to increased intracranial
pressure [2]. The most common symptoms include
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Abstract Subependymomas are
benign intraventricular tumors with
an indolent growth pattern, which
are usually asymptomatic, and most
commonly occur in the fourth and
lateral ventricles. When symptom-
atic, subependymomas often
obstruct critical portions of the
cerebrospinal fluid (CSF) pathway,
causing hydrocephalus, and range
from 3 cm to 5 cm in size. We report
a case of an unusually massive
subependymoma of the lateral ven-
tricles treated with subtotal resec-
tion, ventriculoperitoneal shunt, and
post-surgical radiation. The clinical
course, radiographic and pathologic
characteristics of this massive intra-
ventricular subependymoma are
discussed, as well as the differential
diagnosis of lateral ventricular
masses and a review of the literature
concerning subependymomas.
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vomiting [8]. We present a young male with a large
symptomatic intraventricular subependymoma, discuss
the clinical course, differential diagnosis, and provide a
review of the literature concerning intraventricular
subependymomas.
Case report
A 20-year-old Chinese male attending college in the
United States presented with a complaint of intermittent
severe occipital headaches for 2 years that had become
more frequent and debilitating in nature. He did not
have visual symptoms, nausea, or vomiting. On physical
examination, visual acuity was 20/70 OU with horizon-
tal end gaze nystagmus to both sides with a latent
component. Funduscopic exam was notable for chronic
papilledema. The rest of the physical and neurological
examination was normal.
A non-contrast head computed tomography (CT)
revealed a large symmetric isodense intraventricular
mass without calcification occupying the right and left
lateral ventricles, extending into the temporal horns
(Fig. 1). A subsequent magnetic resonance imaging
(MRI) scan demonstrated this mass to be primarily
isointense to gray matter on T1-weighted images and
hyperintense on T2-weighted images, with minimal
enhancement after administration of dimeglumine gad-
opentetate (Figs. 2 and 3). The mass caused expansion
and scalloping of the lateral ventricles. The third and
fourth ventricles were of normal size.
In 2001, a stereotactic biopsy was performed via a
right frontal bur hole. Several specimens were taken at
various depths and trajectories within the tumor. His-
tological examination of the biopsy revealed choroid
plexus with xanthoma cells but no cholesterol clefts or
granulomatous inflammation, and the diagnosis of
probable xanthogranuloma was made. Because of the
benign nature of this lesion, the lack of obstruction of
the cerebrospinal fluid (CSF) pathway, and the patient’s
report of a decrease in his symptoms after biopsy, a
decision was made to monitor the patient’s symptoms
and follow this lesion clinically and with imaging.
The patient remained relatively asymptomatic for
approximately 18 months, taking acetaminophen for his
headaches with relief. MRI evaluation at 6, 12, and
18 months demonstrated slow interval growth in the
intraventricular mass with development of cerebellar
tonsillar ectopia, but no evidence of CSF outflow
obstruction. While traveling abroad, his headaches
worsened and he visited an emergency room where a
head CT scan demonstrated little change in the size of
the tumor, but was concerning for the increasing
encroachment of the uncus onto the basal cisterns. He
was placed on acetazolamide in order to decrease the
production of CSF and, again, he symptomatically im-
proved.
The patient did well for approximately another
6 months and then presented to the emergency room
with a 3-h history of severe headache and altered mental
status. On physical examination, the patient was unable
to follow verbal commands but localized briskly. A
subsequent noncontrast head CT scan demonstrated a
stable appearance of the large intraventricular mass. A
right frontal ventriculostomy catheter was immediately
placed. The extent of the large intraventricular mass
Fig. 1 Axial pre- (a) and post- (b) contrast-enhanced computed
tomography (CT) of the head shows a large symmetric isodense
intraventricular mass without calcifications filling the lateral
ventricles and extending into the temporal horns
Fig. 2 Axial T2-weighted (a)
and fluid attenuation inversion
recovery (FLAIR) images (b, c)
show a large symmetric hyper-
intense intraventricular mass
that fills the lateral ventricles
(a, b) and the temporal
horns (c)
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precluded total resection, which would require bilateral
craniotomies, a high-risk procedure. Consequently, the
patient was taken urgently to the operating room for a
right frontal craniotomy with an interhemispheric
transcallosal approach for tumor debulking. The tumor
was resected from the frontal horn and the body of both
the right and left lateral ventricles. The Foramen of
Monro was identified and decompressed bilaterally. A
ventriculostomy catheter was left in place in order to
drain cerebrospinal fluid and monitor intracranial
pressure. It was estimated that 10–15% of the mass was
resected. Histopathologic evaluation demonstrated fea-
tures compatible with subependymoma, including a
hypocellular tumor with a dense pink fibrillary matrix
and microcysts. Glial fibrillary acid protein stain was
faintly positive and the MIB-1 index was near zero. No
mitotic figures were present (Fig. 4).
After surgery, the patient improved and was able to
follow commands by the second post-operative day.
However, the patient’s intracranial pressure remained
elevated and he required a ventriculoperitoneal shunt
which was placed into the right frontal horn with an
adjustable valve set to the highest setting.
Due to the large residual tumor burden and prior
reports of some beneficial response to radiation therapy
[5], the patient underwent radiation therapy with the
goal of preventing any further tumor progression.
Whole ventricular radiation therapy was performed
using a three-field technique to a total dose of 45 Gy in
addition to a 5.4 Gy boost in areas of bulky remaining
disease. The patient tolerated radiation therapy well and
remains highly functional, having recently completed
graduate school and reporting no changes in vision or
memory. Follow-up MRI at 6 months shows no evi-
dence of interval increase in the large residual intra-
ventricular tumor (Fig. 5). Further surgical intervention
will only be considered if the patient develops evidence
of tumor progression.
Discussion
Subependymoma is a rare, usually asymptomatic benign
neoplasm that occurs more often in males than females.
The presence of symptoms has been shown to directly
correlate with tumor size, with the majority of symp-
Fig. 4 Resection specimen reveals a subependymoma, as charac-
terized by nests of tumor cell nuclei and microcysts in a fibrillary
stroma
Fig. 3 Axial (a) and coronal T1-weighted (b) post-contrast-
enhanced images demonstrate an intraventricular mass with
minimal enhancement occupying the lateral ventricles and extend-
ing into the temporal horns
Fig. 5 Axial T2-weighted (a),
FLAIR (b), and T1-weighted
(c) post-contrast-enhanced
images demonstrate a slight
debulking of the tumor after
surgery with CSF present in the
frontal horns of the lateral
ventricle. The patient has a
right frontal ventriculoperito-
neal shunt catheter in place and
is presently asymptomatic
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tomatic subependymomas measuring 3–5 cm or greater
in size [2, 6]. Symptom occurrence has also been shown
to be dependent upon tumor location, with supratento-
rial lesions more often symptomatic than fourth-ventri-
cle tumors [2]. In symptomatic patients with
subependymomas of a smaller size, the tumor was often
obstructing a critical part of the cerebrospinal fluid
(CSF) pathway [6]. Two previous reports have found the
presence of hydrocephalus to be critical to and correlate
with symptomatology. In both studies, 88% of symp-
tomatic patients demonstrated hydrocephalus [2, 6],
while hydrocephalus was absent in 47 cases of asymp-
tomatic subependymomas [2].
The World Health Organization classifies sube-
pendymoma as a grade 1 neoplasm. The tumor was
originally described as consisting of primarily ectoder-
mal elements derived from the subependymal glia [1].
However, the histological origin of subependymoma has
remained controversial, reflected in the multitude of
names previously ascribed to this tumor, including
subependymal astrocytoma, subependymal glomerate
astrocytoma, and subependymal mixed glioma [12–14].
In the 1970s, electron microscopy of subependymoma
demonstrated a mixed population of ependymal cells,
astrocytes, and intermediate morphology bipotential
cells with the capability of differentiating into ependy-
mal cells or astrocytes [12, 13]. The presence of a mixed
population of cells within subependymoma has led to
multiple hypotheses over the years regarding its origin,
including arguments that it is truly an ependymal neo-
plasm with a reactive astrocytic component [12] versus
an overlap neoplasm of astrocytoma and ependymoma
[15] versus a hamartomatous lesion arising from mature
subependymal tissue with neoplastic potential [13].
Others have argued that subependymoma represents a
unique tumor that arises from an ependymal glial pre-
cursor cell [14]. A recent report has suggested that the
bland microscopic appearance and low MIB-1 labeling
index of subependymoma support the hypothesis that it
may actually represent a hamartoma rather than a
neoplasm [8].
Light microscopy characteristics of subependymoma
include a hypocellular tumor with isomorphic clusters of
subependymal cells within a dense glial fibrillary matrix.
Microcystic degeneration is frequent and most sube-
pendymomas are hypovascular. Common degenerative
changes such as vascular sclerosis, calcium deposition,
hemosiderin deposition, and thrombosis are more likely
to occur in longstanding or large tumors [2, 5, 8].
Mitoses are rare and the slow growth of this neoplasm is
evidenced by its low MIB-1 labeling index [8].
Computed tomography (CT) characteristics of sube-
pendymoma most commonly include a lobulated, well
defined intraventricular mass that is hypodense or iso-
dense to brain parenchyma with no paraventricular
extension [5, 9, 16, 17]. Rarely, hyperdense subependy-
momas have been reported [6, 7]. The majority of
subependymomas are solid or solid with areas of cystic
degeneration [11, 16, 17]. Calcification is common,
occurring in 32% of cases [16]. CT enhancement char-
acteristics of subependymoma are variable, with no
enhancement, minimal enhancement, heterogeneous
enhancement, and marked enhancement having all been
reported [3–5, 9, 11, 16].
Magnetic resonance imaging (MRI) characteristics
commonly include a well defined solid or mixed solid
and cystic intraventricular mass, the solid component of
which is hypo or isointense on T1-weighted images and
hyperintense on T2-weighted images [5, 7, 9, 11, 17–20].
The heterogenous signal commonly seen in subependy-
momas correlates well with histopathologic findings,
including necrosis, calcification, microcystic change, and
hemorrhage [19, 21]. Peritumoral edema is an infrequent
feature. Similar to CT, MRI enhancement characteris-
tics are variable, including no enhancement, minimal,
heterogeneous, or intense enhancement [7, 17, 19, 20]. A
previous study evaluating the MRI characteristics of 19
reported subependymomas found that 12 of the 19 tu-
mors demonstrated no or minimal enhancement, while 7
of the tumors demonstrated moderate or marked
enhancement that was often partial or irregular [19].
MRI has proven most useful in defining the size and
extent of the tumor, as well as its relationship to other
anatomical structures, such as vasculature, playing a
critical role in pre-operative planning.
Included in the differential diagnosis of lateral ven-
tricular masses are choroid plexus papilloma, central
neurocytoma, subependymal giant cell astrocytcoma,
meningioma, metastasis, subependymoma, and ependy-
moma. Age, location, and some imaging features are
helpful in narrowing this large differential diagnosis.
Choroid plexus papillomas most commonly occur in
young patients and intensely enhance after contrast
administration [10]. Central neurocytomas are similar to
subependymomas in their cystic appearance but are
usually isointense with grey matter on both T1- and T2-
weighted sequences, whereas subependymomas are al-
most always hyperintense on T2-weighted images [7].
Subependymal giant cell astrocytomas always occur
near the Foramen of Monro, calcify frequently, in-
tensely enhance, and are often associated with ventric-
ular wall calcification [7, 10, 16]. Meningiomas,
similarly, frequently calcify and intensely enhance.
Metastasis and malignant gliomas are more likely to
grow rapidly and often lack calcification [3].
Lateral intraventricular subependymomas appear to
have some distinguishing features, often including poor
contrast enhancement [6, 22] and lack of calcification [6].
In contrast to lateral ventricular subependymomas,
fourth-ventricle subependymomas are more likely to
have calcification and contrast enhancement, precluding
distinction from ependymoma [6]. Age may be helpful in
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this regard as only 18% of symptomatic subependymo-
mas occurred in patients less than 15-years-old in one
study, while ependymomas more commonly occur in
children and young adults [16]. In addition, ependy-
moma is more likely to be hyperdense on precontrast CT
than subependymoma [16].
The distinction between supratentorial subependy-
momas from ependymomas is less difficult. Supratento-
rial ependymomas are often paraventricular compared
to subependymomas, which are usually entirely intra-
ventricular. Because subependymomas are usually
intraventricular, they are also more often associated
with hydrocephalus than ependymomas [16]. As previ-
ously discussed, on precontrast CT, ependymomas are
more likely to be hyperdense and, though both supra-
tentorial ependymoma and subependymoma may have
calcification, cyst formation, and contrast enhancement,
these features more commonly occur in supratentorial
ependymomas [16].
Optimal therapy for symptomatic subependymomas
is complete surgical excision. This can often be achieved
with supratentorial subependymomas, given that these
tumors are usually well demarcated, avascular, and
noninvasive [5, 11, 16]. Fourth-ventricle subependymo-
mas, however, frequently arise from the floor of the
fourth ventricle and the likelihood of cranial nerve in-
jury often precludes complete surgical resection [3, 5, 11,
20]. Perioperative mortality rates as high as 42% have
been reported with surgical resection of fourth-ventricle
subependymomas [3]. At the Mayo Clinic between 1975
and 1989, the need for post-operative tracheostomy de-
creased from 50% to 15%, and the perioperative mor-
tality rate decreased from 25% to 0% when compared to
patients operated on from 1950 to 1974 [16]. In cases of
symptomatic fourth-ventricle subependymomas where
complete resection cannot be achieved, surgery should
be directed towards debulking and improving CSF
outflow [3, 5, 17].
Most authors do not advocate post-operative radia-
tion therapy after complete surgical resection of pure
subependymoma as there is a good prognosis with sur-
gery alone [5, 9, 16, 17]. Lombardi et al. reported follow-
up data in 21 patients who underwent surgery for
subependymoma and found that, of the 19 patients who
survived the perioperative period, 12 underwent gross
total resection with no evidence of tumor recurrence or
tumor-related death [5]. The remaining seven patients
were treated with radiation therapy and follow-up
imaging demonstrated a greater radiographic response
at doses of 5,000 cGy or greater, supporting an argu-
ment for radiation therapy in patients with residual tu-
mor or evidence or tumor progression [5]. More
recently, a rare instance of subependymal seeding after
subtotal resection and radiosurgery has been suggested
to account for intraventricular tumor spread in one case.
However, we have no evidence to support seeding in our
patient [23].
We conclude that intraventricular subependymomas
are rare, often asymptomatic masses. When they are
large, they become symptomatic due to CSF outflow
obstruction causing hydrocephalus. Intraventricular
subependymomas have some distinguishing MRI and
CT features that make them unique from other lateral
ventricular masses. The best treatment for a symptom-
atic subependymoma is total resection and, if this is not
possible, debulking of the tumor followed by radiation
therapy. As in this situation, some patients will require
shunting for unresolved hydrocephalus.
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